Last updated: February 20, 2026
What is the Drug?
NDC 66758-0250 corresponds to Vaxneuvance, a pneumococcal conjugate vaccine developed by Merck. It was approved by the FDA in July 2022 for active immunization to prevent invasive pneumococcal disease in adults aged 18 years and older. The vaccine is a 15-valent pneumococcal conjugate designed to expand protection compared to earlier vaccines like Prevnar 13.
Market Size and Drivers
Target Population
- Estimated US adults aged 18+: approximately 258 million (U.S. Census Bureau, 2021).
- High-risk groups include immunocompromised patients, the elderly, and certain chronic disease populations, representing approximately 30-40 million individuals.
Epidemiology
- Pneumococcal disease causes around 3,000 hospitalizations annually in adults over 65 in the U.S. (CDC, 2021).
- Vaccine uptake is historically low, with only about 65% of eligible adults receiving pneumococcal vaccines, creating growth potential.
Competitive Landscape
- Prevnar 13 (PCV13), licensed in 2010, remains the dominant vaccine with annual sales exceeding $2 billion globally.
- Pneumovax 23 (PPSV23), a polysaccharide vaccine, is also widely used.
- Vaxneuvance is the first 15-valent conjugate vaccine in the US approved for adults, aiming to complement and compete with Prevnar 13 and PPSV23.
Market Entry Impact
- Vaxneuvance offers broader serotype coverage (15 vs. 13 of Prevnar 13) and an immunogenic profile targeting adult populations.
- It introduces a new option for healthcare providers, potentially increasing overall vaccination rates.
Pricing Overview
Current Pricing Benchmarks
- Prevnar 13: approximately $150-$180 per dose (Medicare Part B, retail price).
- Pneumovax 23: approximately $75-$125 per dose.
- Vaxneuvance launch price estimated between $165-$200 per dose, based on industry reports and initial pricing data.
Price Factors
- Manufacturer list price: around $185 per dose.
- Reimbursement rates: Medicare and private insurers' negotiated rates impact net revenue.
- Market access negotiations could lower out-of-pocket costs for patients, influencing utilization.
Price Projections (Next 3-5 Years)
| Year |
Estimated Avg Price (USD) |
Notes |
| 2023 |
$180 |
Launch price considering competitive positioning |
| 2024 |
$170-$180 |
Slight reductions expected through market access negotiations |
| 2025 |
$165-$175 |
Price stabilization with increased market penetration |
| 2026 |
$165 |
Price stabilizes as competition and reimbursement solidify |
Market Penetration Assumptions
- Initial uptake is conservative, around 5-10% of eligible adults in the first year.
- Growth accelerates to 15-20% penetration by year three due to increased awareness and provider acceptance.
- Price erosion is limited, as vaccine supply constraints and manufacturing costs keep prices relatively stable.
Revenue Projections
- Conservative estimate for US sales reaching $300 million in 2023, rising to $600-$700 million by 2025.
- Growth driven by increased provider adoption, expanded indications, and higher vaccination rates among vulnerable groups.
Key Market Trends
- Preference shift towards conjugate vaccines in adults.
- Growing awareness of pneumococcal disease severity.
- Public and private payer policies favoring expanded vaccination coverage.
- The potential impact of future combination vaccines or generics not anticipated for several years.
Regulatory and Policy Influences
- CDC’s Advisory Committee on Immunization Practices (ACIP) recommends pneumococcal vaccines for high-risk groups and adults aged 65+.
- Reimbursement policies favoring newer vaccines with broader coverage.
- Ongoing clinical trials assessing efficacy may influence pricing and adoption.
Regulatory Status
- Approved by the FDA in July 2022.
- Pending or approved in other markets, including Europe and Asia, which could influence global pricing strategies.
Conclusion
Vaxneuvance enters a competitive pneumococcal vaccine market with potential to capture significant share among adult, high-risk, and immunocompromised populations. Its adoption hinges on pricing strategies, reimbursement policies, and provider awareness. Price is expected to hover around initial launch levels, with modest reductions over time driven by market dynamics.
Key Takeaways
- NDC 66758-0250 (Vaxneuvance) has an estimated launch price of ~$185 per dose.
- Market penetration growth is expected to increase annual US sales from around $300 million in 2023 to over $600 million by 2025.
- Broader serotype coverage and unfavorable competition from Prevnar 13 define its positioning.
- Reimbursement negotiations and provider acceptance will influence market share and pricing stability.
- Price projections suggest limited erosion, with stabilization around $165-$180 per dose in subsequent years.
FAQs
1. What are the main competitive advantages of Vaxneuvance?
It offers coverage of 15 pneumococcal serotypes, two more than Prevnar 13, and targets adult populations with higher immunogenicity.
2. How does the pricing of Vaxneuvance compare to existing vaccines?
Initial pricing is comparable to Prevnar 13 ($150–$180), with potential for slight decreases based on market access negotiations.
3. What are the primary factors influencing its market adoption?
Provider acceptance, reimbursement policies, patient awareness, and clinical guideline updates drive vaccine uptake.
4. What are the barriers to market growth?
Established competition, vaccine hesitancy, and limited reimbursement coverage could slow growth.
5. How might future policy changes affect the market?
Expanding ACIP recommendations, increased reimbursement, and inclusion in vaccination programs could accelerate adoption.
References
- CDC. (2021). Pneumococcal Disease. https://www.cdc.gov/pneumococcal/about/invasive-disease.html
- U.S. Census Bureau. (2021). Population estimates. https://www.census.gov/
- Industry Reports. (2022). Pneumococcal Vaccine Market Analysis.
- Company Press Release. (2022). Merck Announces FDA Approval of Vaxneuvance.
